Phase I/II trial epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Leonard, JP
Coleman, M
Matthews, JC
Chadburn, A
Wegener, WA
Hansen, HJ
Ziccardi, H
Kapushoc, H
Gayko, U
Cesano, A
Fields, SZ
Goldenberg, DM
机构：
[1] Cornell Univ, Weill Med Coll, Ctr Lymphoma & Myeloma, New York, NY USA
[2] Cornell Univ, Weill Med Coll, Div Hematol & Oncol, New York, NY USA
[3] New York Presbyterian Hosp, New York, NY USA
[4] Immunomed Inc, Morris Plains, NJ USA
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1388
引用
收藏
页码：358A / 358A
页数：1
相关论文
共 50 条
  • [1] Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma
    Leonard, JP
    Coleman, M
    Ketas, JC
    Chadburn, A
    Ely, S
    Furman, RR
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Eschenberg, M
    Gayko, U
    Cesano, A
    Goldenberg, DM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) : 3051 - 3059
  • [2] Epratuzumab, a new anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): Phase I/II trial results.
    Leonard, JP
    Coleman, M
    Schuster, MW
    Chadburn, A
    Ely, S
    Yagan, N
    Sharkey, RM
    Hansen, HJ
    Goldenberg, DM
    [J]. BLOOD, 1999, 94 (10) : 92A - 93A
  • [3] Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results
    Leonard, JP
    Coleman, M
    Ketas, JC
    Chadburn, A
    Furman, R
    Schuster, MW
    Feldman, EJ
    Ashe, M
    Schuster, SJ
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Eschenberg, M
    Gayko, U
    Fields, SZ
    Cesano, A
    Goldenberg, DM
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (16) : 5327 - 5334
  • [4] Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
    Strauss, Sandra J.
    Morschhauser, Frank
    Rech, Juergen
    Repp, Roland
    Solal-Celigny, Philippe
    Zinzani, Pier L.
    Engert, Andreas
    Coiffier, Bernard
    Hoelzer, Dieter F.
    Wegener, William A.
    Teoh, Nick K. W.
    Goldenberg, David M.
    Lister, T. Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) : 3880 - 3886
  • [5] Phase I/II radioimmunotherapy trial with 90Y-labeled epratuzumab (LymphoCide™ anti-CD22 monoclonal antibody) in relapsed/refractory non-Hodgkin's lymphoma (NHL).
    Hajjar, G
    Burton, JD
    Sharkey, RM
    Schuster, SL
    Czuczman, M
    Lamonica, D
    Chatal, JF
    Alavi, A
    Stadtmauer, E
    Leonard, JP
    Coleman, M
    Goldenberg, DM
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 156P - 156P
  • [6] Interim results of a phase I/II radioimmunotherapy trial in relapsed/refractory non-Hodgkin's lymphoma (NHL) patients given 90Y-labeled anti-CD22 humanized monoclonal antibody, epratuzumab.
    Hajjar, G
    Sharkey, RM
    Burton, J
    Schuster, S
    Czuczman, M
    Lamonica, D
    Chatal, JF
    Alavi, A
    Stadtmauer, EA
    Leonard, J
    Coleman, M
    Plutchock, J
    Brenner, AI
    Goldenberg, DM
    [J]. BLOOD, 2001, 98 (11) : 611A - 611A
  • [7] Final results of a Phase I/II trial of fractionated radioimmunotherapy (RAIT) with anti-CD22 90Y-epratuzumab tetraxetan in relapsed/refractory non-Hodgkin lymphoma (NHL)
    Goldenberg, D. M.
    Kraeber-Bodere, F.
    Morschhauser, F.
    Petillon, M.
    Huglo, D.
    Meller, J.
    Kirsch, C.
    Kropp, J.
    Le Gouil, S.
    Le Gouil, S.
    Bodet-Milin, C.
    Teoh, N.
    Chatal, J.
    Wegener, W. A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S237 - S237
  • [8] Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of dota-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab
    Chatal, JF
    Harousseau, JL
    Trümper, LH
    Meller, J
    Pfreundschuh, M
    Kirsch, CM
    Naumann, R
    Kropp, J
    Lateiner, JE
    Wegener, WA
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2004, 19 (04) : 525 - 526
  • [9] Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma
    Stein, R
    Qu, ZX
    Chen, S
    Rosario, A
    Shi, V
    Hayes, M
    Horak, ID
    Hansen, HJ
    Goldenberg, DM
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (08) : 2868 - 2878
  • [10] Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Chatal, JF
    Harousseau, JL
    Griesinger, F
    Meller, J
    Renner, C
    Kirsch, CM
    Naumann, R
    Kropp, J
    Wegener, WA
    Goldenberg, DM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 174S - 174S
12345